Financial Contrast: ARS Pharmaceuticals (NASDAQ:SPRY) versus Protalex (OTCMKTS:PRTX)

Protalex (OTCMKTS:PRTX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Protalex and ARS Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalex	0	0	0	0	0.00
ARS Pharmaceuticals	2	0	5	1	2.63

ARS Pharmaceuticals has a consensus target price of $33.80, indicating a potential upside of 295.37%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Protalex.

Profitability

This table compares Protalex and ARS Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protalex	N/A	N/A	N/A
ARS Pharmaceuticals	-42.74%	-21.85%	-15.88%

Institutional and Insider Ownership

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 80.0% of Protalex shares are owned by company insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Protalex and ARS Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalex	N/A	N/A	N/A	N/A	N/A
ARS Pharmaceuticals	$89.15 million	9.48	$8.00 million	($0.49)	-17.45

ARS Pharmaceuticals has higher revenue and earnings than Protalex.

Summary

ARS Pharmaceuticals beats Protalex on 6 of the 10 factors compared between the two stocks.

About Protalex

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.